GLP-1 receptor agonist use does not increase insulin discontinuation with type 2 diabetes

MedicalXpress | 七月 16, 2026

For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not increase the rate of insulin discontinuation compared with other glucose-lowering agents, according to a study published online July 14 in the Annals of Internal Medicine.